PRME — Prime Medicine Balance Sheet
0.000.00%
- $220.35m
- $29.91m
- $2.98m
Annual balance sheet for Prime Medicine, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 53.3 | 270 | 294 | 122 | 190 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 53.4 | 271 | 297 | 143 | 212 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.596 | 15.7 | 48.6 | 36.6 | 71.6 |
Other Long Term Assets | |||||
Total Assets | 54.8 | 302 | 360 | 194 | 298 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 19.4 | 58 | 26.7 | 56.4 | 38 |
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Liabilities | 21.3 | 62.3 | 44 | 60.8 | 144 |
Redeemable Preferred Stock | |||||
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Unrealized Gain / Loss | |||||
Total Equity | 33.5 | 240 | 316 | 133 | 153 |
Total Liabilities & Shareholders' Equity | 54.8 | 302 | 360 | 194 | 298 |
Total Common Shares Outstanding |